CA
MCRB icon

Continuum Advisory’s Seres Therapeutics MCRB Stock Holding History

Continuum Advisory’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-48
Closed -$669 – 1112
2025
Q1 		$669 Hold
48
– – ﹤0.01% 1557
2024
Q4 		$794 Hold
48
– – ﹤0.01% 1657
2024
Q3 		$565 Hold
48
– – ﹤0.01% 1759
2024
Q2 		$691 Hold
48
– – ﹤0.01% 1542
2024
Q1 		$984 Buy
+48
New +$1.03K ﹤0.01% 1467

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Continuum Advisory's MCRB Position: Q2 2025 in Review

Continuum Advisory sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 48 shares — an estimated $669 sold.

Continuum Advisory first reported a position in MCRB in Q1 2024 and held it in 5 quarters. The position peaked at $984 in Q1 2024. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Continuum Advisory reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 48 Seres Therapeutics shares in Q2 2025, an estimated $669.
  • Continuum Advisory first reported a position in Seres Therapeutics in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Seres Therapeutics position peaked at $984 in Q1 2024.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.